OTCM
GNGBY
Market cap5.73bUSD
Jul 09, Last price
21.03USD
1D
2.04%
1Q
1.82%
Jan 2017
30.62%
Name
Getinge
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||